Advertisement
Screener

REPLIMUNE GROUP, INC. (REPL) ROE

Replimune Group, Inc. ROE

Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Replimune Group, Inc. roe for the quarter ending 2026-06-30 was -281.14%, a change of -197.92% year-over-year.
  • Replimune Group, Inc. roe for the quarter ending 2026-03-31 was -188.94%, a change of -129.47% year-over-year.
  • Replimune Group, Inc. roe for the quarter ending 2025-12-31 was -149.55%, a change of -102.23% year-over-year.
  • Replimune Group, Inc. roe for the quarter ending 2025-09-30 was -117.82%, a change of -61.98% year-over-year.
  • Replimune Group, Inc. roe for fiscal 2026 was -188.94%, a change of -129.47% from fiscal 2025.
  • Replimune Group, Inc. roe for fiscal 2025 was -59.47%, a change of -1.85% from fiscal 2024.
  • Replimune Group, Inc. roe for fiscal 2024 was -57.62%, a change of -26.23% from fiscal 2023.
  • Replimune Group, Inc. roe for fiscal 2023 was -31.39%, a change of -2.68% from fiscal 2022.
Available history
2017-03-31 to 2026-06-30
Data captured

Historical ROE

DateROENet income 12 monthNet income 3 monthShareholder equity
2026-06-30-281.14%-$297.01M-$69.77M$105.65M
2026-03-31-188.94%-$313.94M-$73.18M$166.16M
2025-12-31-149.55%-$314.85M-$70.93M$210.54M
2025-09-30-117.82%-$310.26M-$83.10M$263.34M
2025-06-30-83.22%-$280.22M-$86.69M$336.72M
2025-03-31-59.47%-$247.3M-$74.13M$415.84M
2024-12-31-47.32%-$228.24M-$66.34M$482.37M
2024-09-30-55.84%-$213.02M-$53.05M$381.46M
2024-06-30-51.59%-$220.01M-$53.77M$426.45M
2024-03-31-57.62%-$215.79M-$55.08M$374.51M
2023-12-31-49.81%-$209.96M-$51.12M$421.54M
2023-09-30-42.68%-$198.53M-$60.04M$465.17M
2023-06-30-35.33%-$181.59M-$49.55M$514.03M
2023-03-31-31.39%-$174.28M-$49.24M$555.29M
2022-12-31-26.33%-$156.74M-$39.69M$595.35M
2022-09-30-38.20%-$146.73M-$43.10M$384.07M
2022-06-30-32.41%-$132.98M-$42.25M$410.26M
2022-03-31-28.70%-$118.04M-$31.70M$411.23M
2021-12-31-24.65%-$107.84M-$29.67M$437.51M
2021-09-30-21.85%-$99.95M-$29.36M$457.41M
2021-06-30-18.93%-$90.69M-$27.31M$479.02M
2021-03-31-16.22%-$80.87M-$21.50M$498.73M
2020-12-31-14.56%-$75.16M-$21.78M$516.2M
2020-09-30-26.61%-$69.57M-$20.09M$261.39M
2020-06-30-21.82%-$60.61M-$17.49M$277.81M
2020-03-31-28.64%-$52.63M-$15.79M$183.72M
2019-12-31-22.01%-$43.49M-$16.19M$197.57M
2019-09-30-28.99%-$34.98M-$11.14M$120.64M
2019-06-30-23.28%-$30.3M-$9.51M$130.15M
2019-03-31-22.37%-$30.83M-$6.66M$137.86M
2018-12-31-21.66%-$31.03M-$7.67M$143.24M
2018-09-30-18.47%-$27.71M-$6.46M$150.04M
2018-06-3066.94%-$25.91M-$10.04M-$38.7M
2018-03-3169.17%-$19.41M-$7.14M-$28.07M

Annual ROE

DateROENet income 12 monthShareholder equity
2026-03-31-188.94%-$313.94M$166.16M
2025-03-31-59.47%-$247.3M$415.84M
2024-03-31-57.62%-$215.79M$374.51M
2023-03-31-31.39%-$174.28M$555.29M
2022-03-31-28.70%-$118.04M$411.23M
2021-03-31-16.22%-$80.87M$498.73M
2020-03-31-28.64%-$52.63M$183.72M
2019-03-31-22.37%-$30.83M$137.86M
2018-03-3170.19%-$19.7M-$28.07M
2017-03-3166.90%-$7.7M-$11.52M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B